[Advances in the field of drug development. 1].
D000996:Antitussive Agents / Q000627:therapeutic use*; D001552:Benzazepines / Q000627:therapeutic use; D001565:Benzoates / Q000627:therapeutic use; D002490:Central Nervous System / Q000187:drug effects; D002626:Chemistry, Pharmaceutical; D003988:Dibenzothiepins / Q000627:therapeutic use; D004345:Drug Industry; D004987:Ethers / Q000627:therapeutic use; D004988:Ethers, Cyclic / Q000627:therapeutic use; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use*; D001523:Mental Disorders / Q000188:drug therapy; D008795:Metronidazole / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D009294:Narcotics / Q000627:therapeutic use*; D010082:Oxepins / Q000627:therapeutic use; D010600:Pharmacology; D010640:Phenothiazines / Q000627:therapeutic use; D014149:Tranquilizing Agents / Q000627:therapeutic use*; D014227:Triazines / Q000627:therapeutic use
D000996:Antitussive Agents; D001552:Benzazepines; D001565:Benzoates; D003988:Dibenzothiepins; D004987:Ethers; D004988:Ethers, Cyclic; D006993:Hypnotics and Sedatives; D008996:Monoamine Oxidase Inhibitors; D009294:Narcotics; D010082:Oxepins; D010640:Phenothiazines; D014149:Tranquilizing Agents; D014227:Triazines; D008795:Metronidazole
Fortschritte auf dem Gebiet der Arzneimittelentwicklung. 1.